Clinical trials: Blood Platelets
Chronic Myeloproliferative Disorders, Leukemia
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004058
- Testing
- tetradecanoylphorbol acetate
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Polycythemia Vera, Essential Thrombocythaemia
Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History
Philadelphia-negative myeloproliferative neoplasms (MPNs) occur sporadically and are due to somatic mutations in the JAK2 (Janus kinase 2), CALR (calreticulin) and MPL (thrombopoietin receptor) genes.
- Conditions
- Polycythemia Vera, Essential Thrombocythaemia, Myelofibrosis
- Trial name
- NCT06923670
- Testing
- NGS testing, NGS analysis for mutations in genes involved in familial predisposition to hematological malignancies
- Volunteers
- 496 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR)
The Effect of IV Cangrelor and Oral Ticagrelor Study
Major heart attacks are caused by a number of factors, the two major of which are furring up of a coronary artery with atheroma and then sudden clot formation on this area leading to a blockage and interruption of blood flow.
- Conditions
- Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO), ST-segment Elevation Myocardial Infarction (STEMI)
- Trial name
- NCT02733341
- Testing
- Cangrelor, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Idiopathic Thrombocytopenic Purpura
Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)
Thrombopoietin Receptor Agonists (TPO-ra) are novel treatment modalities for patients with refractory Primary Immune Thrombocytopenia (ITP), but only few data are available for long-term effects of these drugs.
- Trial name
- NCT01443351
- Where
- Denmark
- Sponsor
- Zealand University Hospital
Healthy
PCR-Based Detection of Bacterial Agents in Platelet Concentrates and Whole Blood
Using methods of molecular biology bacteria can be detected in blood. In comparison to conventional blood cultures "bacterial DNA" is isolated using a new sample preparation system in platelet apheresis concentrates and in the…
- Trial name
- NCT00482339
- Where
- Germany
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of Jena
Hematological Malignancies Treated With Intensive Chemotherapy
Evolution of Thromboelastography During Tranexamic Acid Treatment
Patients with hematological malignancies are at increased risk of bleeding, especially during intensive chemotherapy. The aim of this study is to compare by thromboelastography changes during the intensive chemotherapy in…
- Trial name
- TTRAP-Bleeding (NCT03801122)
- Testing
- Tranexamic acid
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Thrombocytopenia, Hematologic Malignancy
Function of Platelets Used for Transfusions
Cytotoxic treatment for malignant hematologic disorders often casue thrombocytopenia that can result in life threatening bleedings.
- Trial name
- NCT05038722
- Testing
- Platelet transfusion
- Where
- 2 sites in Sweden
- Volunteers
- 240 people
- Sponsor
- Sofia Ramström
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Studying Fentanyl in Patients With Cancer
RATIONALE: Studying blood samples from cancer patients undergoing pain treatment in the laboratory may help doctors learn more about how pain drugs work in the body.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00899951
- Testing
- fentanyl citrate, pharmacological study
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ITP - Immune Thrombocytopenia
Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure
This study aims to evaluate the efficacy and safety of Ripertamab in combination with Eltrombopag compared to Eltrombopag alone for patients with Primary Immune Thrombocytopenia (ITP) who have not responded to or have relapsed…
- Trial name
- RPE-ITP (NCT06790888)
- Testing
- Ripertamab/Eltrombopag, Eltrombopag
- Volunteers
- 78 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Septic Shock, Platelet Signal Processing Defect
PLatelets Acetyl-CoA Carboxylase Phosphorylation State in SEPtic Shock
Knowing the dramatic increase in thrombin generation during sepsis, our research hypothesis is that AMPK-induced ACC phosphorylation in platelets is increased and that this might modulate platelets metabolism and more…
- Conditions
- Septic Shock, Platelet Signal Processing Defect, Inflammatory Response, Disseminated Intravascular Coagulation
- Trial name
- PLACCSEPS (NCT04107402)
- Testing
- Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay
- Where
- Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant.
- Conditions
- Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01199562
- Testing
- infection prophylaxis and management, laboratory biomarker analysis, flow cytometry
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- City of Hope Medical Center
Thrombocytopenia
French Adult Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is rare. First-line treatment is corticotherapy. Then, several second-line treatments (SLT) are available: splenectomy, off-label rituximab and thrombopoietin-receptor agonists since 2009.
- Trial name
- FAITH (NCT03429660)
- Testing
- Medical information
- Where
- France
- Volunteers
- 10,000 people
- Sponsor
- University Hospital, Toulouse
Chediak-Higashi Syndrome
Study of Chediak-Higashi Syndrome
Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disorder characterized in its classical form by oculocutaneous albinism, a bleeding diathesis, recurrent infection due to abnormal neutrophil and natural killer cell…
- Trial name
- NCT00005917
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Pre-Eclampsia, Hypertension
Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women
Whole blood sample procurement study from pregnant women with signs and symptoms of Preeclampsia.
- Conditions
- Pre-Eclampsia, Hypertension, Proteinuria in Pregnancy, Thrombocytopenia
- Trial name
- NCT03767803
- Testing
- Non-interventional study
- Where
- 24 sites in United States
- Volunteers
- 344 people
- Sponsor
- Progenity, Inc.
HIV Seropositivity
Interaction Between HIV and Platelets
The investigators propose that the lack of immune response in InR is driven by HIV-containing platelets that might interact with macrophages and CD4+ T-cells although by different mechanisms.
- Trial name
- PLAQUEVIH (NCT04062825)
- Where
- France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Thrombocytopenia Purpura, Chronic HBV Infection
to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection
Primary Objective: To evaluate the efficacy of 6-week Eltrombopag to treat immune thrombocytopenia with chronic hepatitis B virus infection.
- Trial name
- NCT03664518
- Testing
- Eltrombopag
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Immune Thrombocytopenia
Use of Vitamin D as An Adjuvant Treatment in Children With Chronic Idiopathic Thrombocytopenic Purpura
Immune thrombocytopenia is an autoimmune disease in which platelets are targeted by the host immune system. Platelet depletion occurs when autoantibodies targeting glycoproteins (αIIb-β3 and GPIb) found on the surface of…
- Trial name
- MansouraU (NCT06073925)
- Testing
- VIT D
- Volunteers
- 30 people
- Sponsor
- Mansoura University
Sjogren Syndrome With Other Organ Involvement
Tacrolimus for Thrombocytopenia in SS
This 12-week randomized, open-label study evaluates the efficacy and safety of Tacrolimus for Sjogren's syndrome patients with thrombocytopenia.
- Trial name
- NCT05678335
- Testing
- Hydroxychloroquine, Tacrolimus
- Volunteers
- 54 people
- Sponsor
- Peking Union Medical College Hospital
Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
The main purpose of this study is to confirm the correct dose of efgartigimod IV for treating patients aged 12 to younger than 18 years with chronic immune thrombocytopenia (ITP).
- Conditions
- Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
- Trial name
- Advance Jr (NCT07194850)
- Testing
- Efgartigimod IV
- Where
- 26 sites in France, Germany and 8 more
- Volunteers
- 24 people
- Sponsor
- argenx
Immune Thrombocytopenic Purpura (ITP)
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making it easier to bruise or bleed.
- Trial name
- NCT06948318
- Testing
- Mezagitamab
- Where
- 118 sites in United States, Australia and 13 more
- Volunteers
- 150 people
- Sponsor
- Takeda